Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study

European Journal of Nuclear Medicine

Volumn 24, Issue 4, 1997, Pages 381-389

  McQuarrie, S A ^a   MacLean, G D ^a,b,c   Boniface, G R ^c   Golberg, K ^b   McEwan, A J B ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Biomira Inc   (Canada)

Author keywords

Breast adenocarcinoma; Monoclonal antibody; Pharmacokinetics; Radiation dosimetry; Radioimmunoscintigraphy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 170H 82; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSIMETRY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; FEMALE; HUMAN; KIDNEY; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; SCINTISCANNING;

EID: 0030939480     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00881809     Document Type: Article

References (35)

1. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA Cancer J Clin 1991; 41: 146-165.
2. Kopans DB. Breast imaging. Philadelphia: Lippincott, 1989.
3. Kopuns DB. The positive predictive value of mammography. AJR 1992; 158: 521-526.
4. Schmidt JG. The epidemiology of muss breast cancer screening - a plea for a valid measure of benefit. J Clin Epidemiol 1990; 43: 215-225.
5. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy patients. J Clin Oncol 1993; 11: 1536-1544.
6. Rubin E. Critical pathways in the analysis of breast masses. RadioGraphics 1995; 15: 925-927.
7. 111In. Nucl Med Commun 1992; 13: 11-19.
8. Longenecker BM, Willans DJ, MacLean GD, et al. Monoclonal antibodies and synthetic tumor associated glycoconjugates to study the expression of Thomsen-Friedenreich (TF)-like and Tn-like antigens on human cancers. J Natl Cancer Inst 1987; 78: 489-496.
9. Samuel J, Noujaim AA, MacLean GD, et al. Analysis of human tumor associated Thomsen-Friedenreich antigen. Cancer Res 1990; 50: 4801-4808.
10. Harris CC, Greer KL, Jaszczak RJ, et al. 99m-Tc attenuation coefficients in water-filled phantoms determined with gamma cameras. Med Phys 1984; 11: 687.
11. Bailey DL, Hutton BF, Walker PJ. Improved SPECT using simultaneous emission and transmission tomography. J Nucl Med 1987; 28: 844.
12. Ediss C, Tam YK. An interactive program for determining areas bounded by drug concentration curves using Lagrange interpolation. J Pharmacol Toxicol Methods 1995; 34: 165-168.
13. Cloutier SR, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25: 147-161.
14. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York. NY: Society of Nuclear Medicine, 1988.
15. Xue LY, Noujaim AA, Sykes TR, et al. Role of transchelation in the uptake of Tc-99m antibodies in the liver and kidney. Q Nucl Med, in press.
16. 99mTc labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary recurrent metastatic breast cancer. Int J Cancer 1991; 47: 865-869.
17. Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med 1993; 34: 1067-1074.
18. Lamki LM, Buzdar AU, Singletary SE, et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 1991; 32: 1326-1332.
19. Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Eur J Nucl Med 1995; 22: 645-651.
20. van Krooneburgh MJPG, Pauwels EJK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant disease. Nucl Med Commun 1988; 9: 919-930.
21. Reynolds JC, del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol 1989; 16: 121-125.
22. Janssen JAMJL, Blankestijn PJ, Docter R, et al. Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumor marker. Br Med J 1989; 298: 1511-1513.
23. Bischof Delaloye A, Delaloye B, Rudiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J Nucl Mcd 1995; 22: 571-580.
24. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994; 178: 491-497.
25. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
26. m-MIBI mammoscintigraphy of breast masses: early and delayed imaging. Nucl Med Commun 1995; 16: 150-156.
27. Burak Z, Argon M, Memis A, et al. Evaluation of palpable breast masses with Tc-99m MIBI: a comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
28. Lam WWW, Yang WT, Chan YL, et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography. Eur J Nucl Med 1996; 23: 498-503.
29. Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings and potential. AJR 1995; 164: 19-30.
30. Beany RP. Positron emission tomography in the study of human tumors. Semin Nucl Med 1984; 14: 324-341.
31. 18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61-66.
32. 18F]fluoro-D-glucose. N Engl J Med 1991; 324: 200.
33. Nieweg OE, Kim EE, Wong W-H et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
34. Institute for Clinical PET Breast Cancer Task Force. Positron emission tomography - clinical application and economic implications of PET in the assessment of axillary lymph node involvement in breast cancer: a retrospective study. Abstract from the 1994 ICP Meeting
35. Kotz D. Scintimammography: magic bullet or false promise? J Nucl Med 1995; 36: 15N-20N.